ARUP LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Chief Medical Officer

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	8/17/1952
Gender:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Hepatocellular Carcinoma Tumor Marker Panel

ARUP test code 0081326

Alpha Fetoprotein Total	48 ng/mL	H	(Ref Interval: 0-15)
Alpha Fetoprotein L3 Pct	47.0 %	H	(Ref Interval: 0.0-9.9)

INTERPRETIVE INFORMATION: Alpha Fetoprotein L3 Percent

The uTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably.

The AFP-L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases.
Patients with elevated serum AFP-L3 percent should be more intensely evaluated for evidence of hepatocellular carcinoma since elevated values have been shown to be associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
For pregnant females, the result is not interpretable as a tumor marker.

Des-gamma-carboxy Prothrombin	25.5 ng/mL	H	(Ref Interval: 0.0-7.4)

INTERPRETIVE INFORMATION: Des-gamma-carboxy Prothrombin

The uTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The des-gamma-carboxy prothrombin (DCP) assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated DCP values have been shown to be associated with an increased risk for developing hepatocellular carcinoma. Patients with elevated serum DCP should be more intensely evaluated for evidence of hepatocellular carcinoma. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Medication containing vitamin K preparations may cause a negative bias of the DCP values.
Medication containing vitamin K antagonist or antibiotic may cause a positive bias of the DCP values.

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Alpha Fetoprotein Total	22-026-138130	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alpha Fetoprotein L3 Pct	22-026-138130	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Des-gamma-carboxy Prothrombin	22-026-138130	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical